משתמש:Ybruner/BSP Medical

BSP Medical is a company, manufacturing software applications under the brand name HyperQ. Its products are based on analyzing high frequency ECG signals and can provide early detection for cardiac conditions. BSP Medical is a private company wholly owned by Israel China Biotechnology (ICB) Ltd. (TASE:ICB) and is a constant development of the next stage of early detection, in an effort to save lives of people at risk of heart attach.

History

The company established at November 1999 under the name Biological Signal Processing Ltd., founded by seasoned researchers in the field of high frequency ECG analysis. The company made an IPO at May 2006 in Tel Aviv Stock Exchange and became a public company. Since its establishment the company made a research, development, production, marketing and sales of technology and medical devices for the detection and analysis of ischemic heart disease based on advanced analysis of ECG signals, using company's proprietary algorithms. The company developed the HyperQ technology, which is based on monitoring the electrical activity of the heart muscle and analysis of the high frequency signal received through the ECG test.

At January 2018, the majority of the company's registered shares were acquired by China Israel Biology Co., Ltd (CIB) and company name changed to Israel China Biotechnology (ICB) Ltd., which established the new company BSP Medical Ltd. that began its operation at the beginning of 2019, where all the technology, intellectual property and knowhow, shifted to BSP Medical in order to resume R&D of the HyperQ technology and to create new applications.

Science

Scientific background:

Conventional ECG interpretation is performed by inspecting the ECG in the 0.05-100 Hz frequency band. Detection of ischemia relies upon recognition of abnormal alterations in the repolarization phase of the cardiac cycle, manifested as changes in the ST segment of the ECG. However, significant research efforts during the last decade have shown that ischemia also induces changes to the depolarization phase. These changes can be detected by examining the high-frequency content of the mid-QRS complex (HFQRS). These high frequency components, resulting from the fragmented waveform of electrical activation of the myocardium, can be filtered from high resolution ECG signals in the 150 to 250 Hz frequency band. As these components are very low in amplitude (measured in µV), sophisticated computer analysis is required to reliably extract them.

The HyperQ™ Signal Analysis:

High-resolution ECG acquisition hardware, employing a sampling rate of 1000Hz and using standard, conventionally-placed ECG electrodes, is used to record the ECG signal.

HyperQ™ technology uses a multifaceted process to interpret the information acquired by the ECG hardware. This process includes identification of the QRS complex, rejection of corrupted signals, several alignment procedures, signal to noise enhancement, and filtering

The HyperQ analysis can be used for several clinical processes. First, it can be used in a stress ECG test to improve the diagnosis of Coronary Artery Disease (CAD). In this case, it can accurately detect the development of demand ischemia by monitoring the changes of the HFQRS throughout the exercise – from the resting phase, through peak exercise until the recovery phase, when the patient returns to her baseline signal. Second, it can be used in a resting ECG test to improve the diagnosis of Acute Coronary Syndrome (ACS) most markedly in the case of Non ST elevation ACS, where conventional ECG is often equivocal. Other cases include continuous ECG monitoring both for bed-side and Holter monitoring, monitoring signals from electrodes of implantable cardiac devices and even telemonitoring applications for home care patients.

Additional information on the Science and its applications can be found at the BSP Medical website.

Technology

HyperQ™ is a suite of algorithms, implemented in software, aimed at the early detection of coronary artery disease (CAD) and ischemia. HyperQ™ technology detects stress-induced and acute resting ischemia. It can be applied in any venue and on any monitoring or diagnostic platform, including Big Data, Telemedicine, Home Care, Wearables, Rest and Stress ECG.

To date, thousands of patients have been diagnosed by HyperQ™ in controlled clinical studies, hospitals and private physician offices. The clinical results were published in leading cardiology journals.

The HyperQ™ revolutionizes the field of diagnosing coronary artery disease (CAD), preventing unnecessary patient exposure to radioactive or invasive procedures and clinical time and cost associated with advanced IHD diagnosis systems. HyperQ™ sensitivity and specificity are similar to those of radioactive procedures, performing equally well in men and women, thus allowing for a dramatically enhanced diagnosis in women.

HyperQ™ is a proprietary and patented technology. It analyses the high-frequency QRS depolarization segment of the cardiac cycle, whereas conventional ECG analysis of the ST segment is related to the repolarization phase of the cycle. HyperQ™ provides superior clinical accuracy to any other non-invasive solution currently available.

The American Heart Association (AHA) included HyperQ™ in its last statement on exercise standards for testing (published in August 2013), pointing out that it has been found to have useful test performance for detection of CAD.

Products

HyperQ AN-S - a unique software module designed to analyze Stress Test ECG based on the detection of changes in the high frequency component of the QRS segment. HyperQ can be integrated in any ECG stress systems or apply in Big Data. HyperQ AN-S is FDA cleared and CE marked.

HyperQ Analyzer Rest - innovative software module for early detection of acute coronary artery disease on any ECG rest systems. Provides a new perspective to the clinical staff, in particular diagnosis of Non-ST Elevation MI (NSTEMI) and Unstable Angina (UA). HyperQ Analyzer Rest is FDA cleared and CE marked.

OEM - BSP’s HyperQ™ technology is integrated into a wide range of medical systems – first and foremost, ECG devices. There are also a range of applications which can be greatly enhanced including home telemonitoring, bedside and Holter monitoring and implantable cardiac devices.

Management

Amir Beker (Chief Executive Officer)

Yehuda Bruner (Chief Operating Officer)

Guy Goldin (Chief Finance Officer)

Noam Omer (R&D Manager)